Glideslope AI-powered market news
No market stories in the last 7 days. The latest coverage is below.
No scored stories in the last 7 days.
| Day | Mood | Stories |
|---|---|---|
| Sun, Oct 11 | — | 0 |
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
Hundreds of Americans have filed personal injury lawsuits against the makers of popular diabetes and weight-loss drugs like Ozempic, Wegovy, and Mounjaro, clai…
The firm upgraded the pharmaceutical stock to buy from hold.
Rosie O'Donnell says Mounjaro is part of why she's 'never felt better' at 64
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.
Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.
The 150-year-old drugmaker is the first company in health care to hit the milestone.
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
(RTTNews) - Eli Lilly and Co. (LLY) announced detailed results from SURPASS-PEDS, the first Phase 3 trial evaluating the safety and efficacy of Mounjaro (tirze…
The recommended UK price will rise by up to 170%, although the impact on consumers could be more limited.
It comes as President Donald Trump pressures drugmakers to lower U.S. drug prices while hiking them abroad under a policy called "most favored nation."
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2 diabetes.
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro.
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.
Lilly's CEO says that the company has "tremendous momentum†entering 2025.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE